A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Stopped Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021.

Conditions

• Multiple Myeloma

Interventions

• DRUG: Melflufen
• DRUG: Pomalidomide
• DRUG: Dexamethasone

Sponsor

Oncopeptides AB